



Governor
Douglas A. Ducey

**ARIZONA BOARD OF OSTEOPATHIC EXAMINERS
IN MEDICINE AND SURGERY**
1740 W. ADAMS ST., PHOENIX, ARIZONA 85007
PH (480) 657-7703 | FX (480) 657-7715
www.azdo.gov | questions@azdo.gov

Board Members:
Jerry G. Landau, J.D., Pres.
Gary A. Erbstoesser, D.O., V.P.
Douglas L. Cunningham, D.O.
Jonathan A. Maitem, D.O.
Jeffrey H. Burg, AIF
Dawn K. Walker, D.O.
Ken S. Ota, D.O.

Executive Director
Justin Bohall

**ARIZONA BOARD OF OSTEOPATHIC EXAMINERS IN MEDICINE AND SURGERY
DRAFT MINUTES FOR MEETING OF COMMITTEE ON COMPLIANCE AND CONFIDENTIAL
PROGRAM FOR TREATMENT AND REHABILITATION OF IMPAIRED PHYSICIANS**

Held virtually on Wednesday, December 2, 2020

Committee Members

Gary Erbstoesser, D.O. – Chair
Jeffrey H. Burg
Dawn K. Walker, D.O.

Other Staff Present

Justin Bohall, Executive Director
Barbara Prah-Wix, D.O., Medical Consultant
Lindsey Castro, Deputy Director
Kim Madrid, Business Manager
Mary Williams, Assistant Attorney General

1. CALL TO ORDER

Dr. Erbstoesser called the committee’s meeting to order at 3:03 pm.

2. ROLL CALL

	Dr. Erbstoesser	Mr. Burg	Dr. Walker
Present	X	X	X
Absent:			

3. REVIEW CONSIDERATION, DISCUSSION, AND ACTION ON THE FOLLOWING ITEMS

A. Presentation from Barbara Prah-Wix, DO – Internal Medical Consultant

Dr. Prah, Medical Consultant for the Board, provided an overview presentation on the Board’s existing compliance and confidential programs.

Also present to provide information on the confidential program was Dr. Michel Sucher and Dr. Eric Lott of Community Bridges.

Dr. Sucher provided an overview of the monitoring program at Community Bridges. Dr. Sucher provided statements to outline his thoughts on relapse. Dr. Lott provided some statements about substance abuse treatment and monitoring focusing on how substance use is and can be treated.

Dr. Erbstoesser inquired about a potential time-frame to work with the licensee with a minor infraction. Dr. Sucher recommended a statement of “You **may be** out of the confidential program if you violate this agreement.” Dr. Sucher stated that most relapse occur within 1 to 2 years of initial treatment.

No Action was taken by the committee.

B. Presentation from Affiliated Monitors Inc.

Vincent DiCianni and Catherine Keyes of Affiliated Monitors Inc., provided an overview presentation of a probationary monitoring program.

Ms. Keyes provided an overview of AMI’s probationary monitoring program and the costs of their program.

No Action was taken by the committee.

C. Current Board Policy on Confidential Substance Abuse Rehabilitation Program and Proposed Revisions to the Policy

Staff provided information on the Confidential Substance Abuse Rehabilitation Program and asked the Committee to consider the current one strike offense that determines eligibility into the confidential program.

Dr. Erbstoesser encouraged staff to stress the consequences of violating the confidential agreement with the licensees.

The Committee will meet again to discuss this item.

D. Effects of Arizona Proposition 207 (Smart and Safe Act) to the Confidential Substance Abuse Rehabilitation Program and Probationary Monitoring Program

The Executive Director provided a memo for the Committee to review regarding Arizona Prop 207 (Smart and Safe Act) to address questions of how other states, where marijuana has been legalized, treat physician impairment. The Committee reference the Colorado Impaired Driver laws that states “By law, drivers with 5 nanograms of delta-9 tetrahydrocannabinol (THC) per milliliter of whole blood can be prosecuted for DUI.”

Dr. Erbstoesser directed staff to draft a policy consistent with the Colorado and California Medical Boards’ and return the policy to the committee for approval.

E. Current management of the Board’s Confidential Substance Abuse Rehabilitation Program and possible contracting with other organizations for future management

Staff provided information regarding the Board’s ability to contract out for the administration of this confidential program. Mr. Burg asked for clarification the fees and the cost of the program.

The Committee will meet again to discuss this item.

4. ADJOURNMENT

MOTION: Mr. Burg moved to adjourn.

SECOND: Dr. Walker

VOTE: 3-yay, 0-nay, 0-abstain, 0-recuse, 0-absent.

MOTION PASSED.

	Vote	Dr. Erbstoesser	Mr. Burg	Dr. Walker
Yes:	3	X	X	X
No:	0			
Abstain/Recuse:	0			
Absent:	0			

The Committee's meeting adjourned at 4:30 p.m.



Justin Boffall, Executive Director